Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2004

View Archived Issues

First patient enrolled in trial of dendritic cell vaccine for melanoma

Extended phase I trial of INT for diabetes

CTX granted for phase IIa trial of ATL-104 for mucositis

Positive proof of concept results for SUDCA

Chiron licenses Coley's VaxImmune

Strategic alliance and IND plans for new DNA-based HIV vaccine

Dynogen to develop Mitsubishi neurological compound for IBS

Novartis files sNDA for new indication for Diovan

Wex files CTA for pivotal Tectin trial

Methylphenidate improves fatigue and physical well being in advanced cancer patients

PGN-0052 advances to phase II

IL-18 vaccination as a potential strategy for treating lupus

HEP DART 2003 meeting highlights: Phase Ib data presented for isatoribine

Merimepodib enhances the anti-HCV activity of PEG-IFN and ribavirin

DMC recommends continuation of phase III Oncophage trial

Cardiome submits oxypurinol NDA

ICA-69673 set to enter phase I

Nastech submits abbreviated NDA for Calcitonin-Salmon nasal spray

Preclinical milestone achieved in Neurogen/Aventis collaboration

Abbott and Protein Design Labs enter IL-12 licensing agreement

Novel anti-Helicobacter pylori agents developed by Shionogi researchers

New anti-herpes virus compounds reported by Yamanouchi and Rational Drug Design

Banyu team reports the preparation and use of new ORL1 antagonists

Bislactone-based acetyl-CoA carboxylase inhibitors newly identified at Ajinomoto

New 5-HT6 modulators, their preparation and use described in Roche patent

Insight into the mechanism of the antilipemic effects of FR-218944

Improved profile of TRA-418 possibly due to dual activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...